Reports are discounted or included with certain Membership Options.

Organ and Tissue Transplantation and Alternatives

Jan 2011| HLC012E| BCC Publishing

Customize Report

Report Highlights

The global market for transplantation products, devices, and pharmaceuticals was valued at nearly $54 billion in 2010 and is projected to grow at an 8.3% compound annual growth rate (CAGR) to reach $80 billion in 2015.

SCOPE OF REPORT

This report offers forecasts, by product segment, from 2010 through 2015, including supporting analyses for projections. Product segments covered consist of solid organ (e.g., kidneys, liver, heart-lung, pancreas, intestines) and the tissue transplantation (e.g., bone, skin, cornea, heart valves) markets, along with the pharmaceuticals that accompany each market.

Also included are experimental xenografts and artificial organs; tissue transplants; and cell transplants (e.g., bone marrow, cord blood, peripheral blood, islet cell). The report touches on the use of fetal cells, stem cells, and altered cancer cells.

The arrangement of this report offers an overview of the key elements in the transplantation process: tissue typing, procurement and preservation, immunosuppressants for solid organ and tissue transplants, and postoperative monitoring. International markets are discussed, and information is provided on industry structure and the regulatory environment.

Within each section are discussions of commercialization opportunities for each segment of the market. New or emerging devices, techniques, and pharmaceuticals are highlighted.

Profiles of more than 50 leading companies involved with solid organ transplantation, tissue transplantation, and alternative technologies are included. The report provides information on company placement within the market and strategic analyses of the companies’ available and emerging products.

An appendix featuring various terms and processes used in transplantation is provided at the end of the report.

This report cites autologous products only in relation to their impact on the market for allografts. It does not include blood products, with the exception of peripheral and umbilical cord blood as a source of stem cells.

ANALYST CREDENTIALS

Peggy S. Lehr is the BCC Research analyst of this report. Ms. Lehr has worked with the publishing arms of for-profit and not-for-profit organizations for more than 25 years, and she specializes in marketing reports on the medical industry. She has contributed several reports on the medical industry for BCC, including reports on the global market for catheters, the sterilization market, reports on pediatric and eldercare markets, and her most recent report on the cardiovascular surgical industry.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com

[+] Show Chapter Details

	Title/Chapter Name	Pages	Price	Member Price
	Full Report: Organ and Tissue Transplantation and Alternatives	233	$2,750	Free
	Chapter- 1: INTRODUCTION	4		Free
REASONS FOR DOING THE STUDY STUDY GOALS AND OBJECTIVES SCOPE OF REPORT METHODOLOGIES AND INFORMATION SOURCES ANALYST CREDENTIALS RELATED BCC REPORTS BCC ONLINE SERVICES DISCLAIMER
	Chapter- 2: SUMMARY	4	$250	Free
Table Summary : PROJECTED GLOBAL MARKET FOR TRANSPLANTATION PRODUCTS AND DEVICES, THROUGH 2015 Figure Summary : PROJECTED GLOBAL MARKET SHARES OF TRANSPLANTATION PRODUCTS AND DEVICES, 2010 AND 2015
	Chapter- 3: INDUSTRY OVERVIEW	26	$307	Free
HISTORY OF TRANSPLANTATION INDUSTRY ACQUISITIONS NECESSARY COMPONENTS TO ORGAN AND TISSUE TRANSPLANTATION OVERVIEW OF THE DONATION PROCESS THE TRANSPLANTATION PROCESS SOLID ORGANS TISSUE TRANSPLANTATION IN THE U.S. TRANSPLANTATION TRENDS OUTSIDE THE U.S. LIMITED SUPPLY CURTAILS TRANSPLANTATIONS KEY FACTORS IN INDUSTRY GROWTH KEY FACTORS INHIBITING GROWTH
	Chapter- 4: TISSUE TYPING TECHOLOGIES	5	$59	Free
PANEL REACTIVE ANTIBODIES TISSUE TYPING TECHNOLOGIES GLOBAL TISSUE TYPING MARKET
	Chapter- 5: SOLID ORGAN PROCUREMENT AND PRESERVATION	16	$189	Free
DEFINITION OF BRAIN DEATH ORGANS OBTAINED FOR TRANSPLANT INCREASING SUPPLY IN THE U.S. THE TRANSPLANT GROWTH AND MANAGEMENT COLLABORATIVE SUPPLY MANAGEMENT ORGAN PROCUREMENT OUTSIDE THE U.S. ALLOCATION CRITERIA IN THE U.S. ALLOCATION CRITERIA IN THE EU SOLID ORGAN PRESERVATION MARKET FOR PRESERVATION SOLUTIONS MACHINE PERFUSION
	Chapter- 6: TISSUE PRODUCTS	23	$271	Free
REGIONAL GROWTH IN TISSUE PRODUCTS SOFT TISSUE ALLOGRAFT MARKET OPPORTUNITIES IN THE TISSUE MARKET HEART VALVES CORNEA BLOOD STEM CELLS CORD BLOOD THE ORTHOBIOLOGICS MARKET SKIN AND COLLAGEN TRANSPLANTS VASCULAR TISSUE TRANSPLANTATION IN THE U.S. COMMERCIAL OPPORTUNITIES IN TISSUE TRANSPLANTATION
	Chapter- 7: IMMUNOSUPPRESSANTS	25	$295	Free
TOLERANCE OF TRANSPLANTED ORGANS USUAL ANTI-REJECTION DRUG PROTOCOLS TYPES OF IMMUNOSUPPRESSANTS CALCINEURIN INHIBITORS ANTI-PROLIFERATIVE AGENTS M-TOR INHIBITORS MONOCLONAL, POLYCLONAL ANTIBODIES TREATMENTS BY STAGE OF PROCEDURE MAINTENANCE THERAPY IMMUNOSUPPRESSANT USE IN REJECTION THERAPY MARKET POSSIBILITIES FOR FUTURE TRANSPLANTATION DRUGS IMMUNOSUPPRESSIVE AGENTS IN DEVELOPMENT
	Chapter- 8: ANTI-INFECTIVES AND POST-TRANSPLANT MONITORING IN ORGAN AND TISSUE TRANSPLANTATION	9	$106	Free
ANTI-INFECTIVES AND IMMUNOSUPPRESSANTS POST-TRANSPLANT MONITORING MARKET OPPORTUNITIES FOR POSTOPERATIVE MONITORING
	Chapter- 9: ALTERNATIVE DEVICES AND TECHNOLOGIES	32	$378	Free
ALTERNATIVES TO CORNEAL TRANSPLANTATION ALTERNATIVES TO INTESTINAL TRANSPLANTATION ALTERNATIVES TO PANCREAS TRANSPLANTATION ALTERNATIVES TO LIVER TRANSPLANTATION ALTERNATIVES TO LUNG TRANSPLANTATION ALTERNATIVES TO BONE GRAFTS ALTERNATIVES TO VASCULAR TRANSPLANTATION ALTERNATIVES TO VASCULAR TRANSPLANTATION ALTERNATIVES TO SKIN TRANSPLANTATION ALTERNATIVES TO HEART TRANSPLANTATION ORTHOPEDIC DEVICES FOR TRANSPLANTATION Table 44 : PROJECTED GLOBAL MARKET FOR TRANSPLANTATION ALTERNATIVE DEVICES, THROUGH 2015
	Chapter- 10: REGULATIONS AND REIMBURSEMENT	6	$71	Free
REGULATIONS IN THE U.S. REGULATIONS OUTSIDE THE U.S. REIMBURSEMENT IN THE U.S. REIMBURSEMENT OUTSIDE THE U.S.
	Chapter- 11: EMERGING PROCEDURES AND PRODUCTS IN DEVELOPMENT	11	$130	Free
MACHINE PERFUSION OF SOLID ORGANS ORGAN PRESERVATION SOLUTIONS IN DEVELOPMENT REGENERATIVE MEDICINE ORGAN REJECTION STRATEGIES STEM CELL RESEARCH ADVANCES IN CARDIOVASCULAR TREATMENTS PHARMACEUTICAL PIPELINE DEVELOPMENT
	Chapter- 12: COMPANY DIRECTORY	67	$791	Free
ABBOTT LABORATORIES ADVANCED BIOHEALING, INC. ALLOSOURCE ARBIOS SYSTEMS, INC. ARTHREX, INC. ASTELLAS PHARMA, INC. BIOMET, INC BIORAD LABORATORIES BRISTOL-MYERS SQUIBB CELERA CORP. CENTACOR ORTHO BIOTECH, LTD. CONMED-LINVATEC CORP. CRYOLIFE, INC. DEPUY ORTHOPEDICS DIAGAST DR. F. KÖHLER CHEMIE GMBH EDWARDS LIFESCIENCES EXACTECH FORTICELL BIOSCIENCE GEN-PROBE, INC. GENZYME W.L. GORE & ASSOCIATES HEMOCLEANSE, INC. INTEGRA LIFESCIENCE INVITROGEN (SEE LIFE TECHNOLOGIES) JOHNSON & JOHNSON KIADIS PHARMA KINETIC CONCEPTS, INC. (KCI) LIFEBLOOD MEDICAL, INC. LIFECELL CORP. (SEE KINETIC CONCEPTS, INC.) LIFECYCLE PHARMA A/S LIFE TECHNOLOGIES LIVING CELL TECHNOLOGIES, LTD. LUMINEX CORP. MEDTRONIC, INC. NOVARTIS AG ONE LAMBDA, INC. ON-X LIFE TECHNOLGIES, INC. ORGANOGENESIS, INC. ORTHO-CLINICAL DIAGNOSTICS OSTEOTECH PDL BIOPHARMA PFIZER, INC. PROTEOME SCIENCES, PLC ROCHE PHARMACEUTICALS RTI BIOLOGICS SMITH & NEPHEW, PLC SORIN GROUP, S.P.A. ST. JUDE MEDICAL STRYKER CORP. SYNCARDIA SYSTEMS, INC. SYNOVIS SURGICAL INNOVATIONS SYTHES (NORTH AMERICA) TEI BIOSCIENCE TEVA PHARMACEUTICALS, LTD. TERUMO MEDICAL CORP. THORATEC CORP. TORNIER, INC. (U.S.) TRANSMEDICS, INC. VIROPHARMA, INC. WORLDHEART CORP. WRIGHT MEDICAL TECHNOLOGY, INC. WYETH (SEE PFIZER) ZIMMER HOLDINGS, INC.
	Chapter- 13: APPENDIX	5	$59	Free
DEFINITIONS

Published - Oct-2008| Analyst - Vicki McConnell| Code - HLC012D

Report Highlights

The U.S. market for organ and tissue transplantation and alternatives was worth $18.9 billion in 2007. The market is projected to grow to $20.9 billion in 2008 and $28.2 billion in 2013, representing a compound annual growth rate (CAGR) of 6.1%.
The solid organ segment has the largest share of the market, worth $9.7 billion in 2007 and an estimated $10.5 billion in 2008. This is expected to grow at a CAGR of 5.7% to reach $13.8 billion in 2013.
Tissue transplantation generated $9.2 billion in 2007. This should increase to $10.4 billion in 2008 and $14.3 billion in 2013, for a CAGR of 6.5%.

Published - Oct-2005| Analyst - Lynn Gray| Code - HLC012C

Report Highlights

The organ and tissue transplantation market in the U.S. is estimated at $11.7 billion in 2005 ad is expected to rise at an average annual growth rate (AAGR) of 5.2% to $15.1 billion by 2010.
The transplantation market is estimated at just under $5 billion in 2005 and is expanding at an AAGR of 4.8%.
The fastest growing sector is small bowel (intestine) transplantation. Kidney and liver transplantation will account for 78% of the total in 2005.
The U.S. tissue transplantation market totaled about $6.8 billion in 2005. It is projected to grow at an AAGR of 5.5%, to $8.9 billion in 2010.

Published - Mar-2003| Analyst - Peter Downs| Code - HLC012B

Report Highlights

Tissue and organ transplantation in the U.S. was a $17.3 billion market in 2002.
This is expected to grow 18% to $20.5 billion by 2007 at an average annual rate (AAGR) of 3.5%.
The fastest growing sector is small bowel transplantation.
Kidney transplantation accounted for 59% of U.S. organ transplants in 2002.

FAQ

Single User License: $2750

Become a Member

Already a member? Login to access this report free.

Have a Question? Ask Us.

Why BCC Research.?

Every purchase provides access to:

Thousands of recently published reports from select publishers
Member Discounts of up to 50% on over 20,000 additional reports from all publishers
Our analysts and research concierge for all inquiries

RELATED REPORTS

Share This Report